Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus FLOT versus FLOT as neoadjuvant therapy for gastric or gastroesophageal junction adenocarcinoma
ChiCTR2000030610Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Mar 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of camrelizumab, docetaxel, oxaliplatin, folinic acid and fluorouracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The Affiliated Hospital of Qingdao University. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
camrelizumabdocetaxeloxaliplatinfolinic acidfluorouracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000030610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030610.